FLT3 and acute myeloid leukemia: Despite the approval of new targeted treatments, including FMS-like tyrosine kinase 3 (FLT3) or antiapoptotic B-cell lymphoma 2 (BCL-2) protein inhibitors, up to 50% of AML patients will eventually relapse or die.